Pharmacovigilance Automation Adoption Survey – UK & US.
Key findings and discussion.
Although a majority of respondents, inpharmacovigilance or product/drug safety roles, appear bullish about their organizations’ pharmacovigilance (PV) automation plans, some ambitions may be unrealistic.
This substantial new survey, conducted with a hefty cross-section of pharmaceutical organizations in the UK and US, exposes a lack of technology awareness and poor appreciation of the rapid ROI associated with automating adverse event case capture.
